Promise of Remimazolam in Pediatric Emergence Delirium

Editorial| September 2024 Promise of Remimazolam in Pediatric Emergence Delirium Pablo M. Ingelmo, M.D.; Pablo M. Ingelmo, M.D. 1Department of Anesthesia, McGill University, Montreal, Canada; Division of Pediatric Anesthesia, and Edwards Family Interdisciplinary Center for Complex Pain, Montreal Children's Hospital, and Research Institute, McGill University Health Center, Montreal, Canada. Search for other works by this author on: This Site PubMed Google Scholar Andrew J. Davidson, M.B.B.S., M.D. Andrew J. Davidson, M.B.B.S., M.D. 2Department of Anaesthesia and Pain Management, Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia; Melbourne Children's Trial Centre, Melbourne, Australia. Search for other works by this author on: This Site PubMed Google Scholar Author and Article Information Accepted for publication June 10, 2024. This editorial accompanies the article on p. 500. Address correspondence to Dr. Ingelmo: A02-3525.1 – 1001 Boul. Decarie, Montreal QC, H41 3J1, Canada. Anesthesiology September 2024, Vol. 141, 434–436. https://doi.org/10.1097/ALN.0000000000005135 Connected Content Article: Effect of Remimazolam on Emergence Delirium in Children Undergoing Laparoscopic Surgery: A Double-blinded Randomized Trial Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Search Site Citation Pablo M. Ingelmo, Andrew J. Davidson; Promise of Remimazolam in Pediatric Emergence Delirium. Anesthesiology 2024; 141:434–436 doi: https://doi.org/10.1097/ALN.0000000000005135 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsAnesthesiology Search Advanced Search Topics: emergence delirium, pediatrics, remimazolam Remimazolam represents an emergent class of benzodiazepine-related compounds with a faster onset and offset than midazolam, integrating features of both midazolam and remifentanil. Remimazolam can also be reversed by flumazenil.1 Once the basic pharmacology of a new agent is defined, the next step is usually to determine whether the agent improves outcomes. Remimazolam is entering into this phase. It is reasonable to perform these efficacy trials exploring dose or mode of administration in tightly controlled groups with a placebo control. The trial by Cai et al. reported in this issue of Anesthesiology is this type of trial.2 The scenarios where the new therapy is trialed should be in areas where the outcome is important. Ideally, they should also be where there is no completely effective therapy or a lack of agreement over the most effective therapy. Emergence delirium is an important problem in pediatric anesthesia. Its... You do not currently have access to this content.